17100-64-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-5-hydroxymethyl-anisole is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and agricultural products.
Used in Flavor and Fragrance Industry:
As a derivative of anisole, 2-Bromo-5-hydroxymethyl-anisole is used as a flavoring agent in food and beverages, enhancing the sensory experience of these products with its characteristic aromatic properties.
Used in Antioxidant and UV Absorber Production:
2-BROMO-5-HYDROXYMETHYL-ANISOLE is utilized as a raw material in the production of antioxidants and ultraviolet absorbers, which are essential for preserving the quality and stability of various products, particularly in the plastics and coatings industries.
Used in Organic Compound Synthesis:
2-Bromo-5-hydroxymethyl-anisole is employed as a versatile intermediate in the synthesis of a wide range of organic compounds, facilitating the creation of new materials and chemical entities for various applications.

InChI:InChI=1/C8H9BrO2/c1-11-8-4-6(5-10)2-3-7(8)9/h2-4,10H,5H2,1H3

Upstream product

• 6971-51-3 3-methoxybenzyl alcohol 
• 56256-14-5 4-bromo-3-methoxy-benzoic acid 
• 99-06-9 3-Carboxyphenol 
• 14348-38-0 4-bromo-3-hydroxybenzoic acid 
• 77-78-1 dimethyl sulfate 
• 17100-63-9 methyl 4-bromo-3-methoxybenzoate 

Downstream Products

• 872516-87-5 {2-methoxy-4-[(tetrahydropyran-2-yloxy)methyl]phenyl}boronic acid 
• 113081-49-5 1-bromo-4-(chloromethyl)-2-methoxybenzene 
• 1148110-16-0 1-bromo-4-(bromomethyl)-2-methoxybenzene 
• 1186304-33-5 C₃₉H₄₂O₈ 
• 1186304-34-6 C₃₁H₃₀O₆ 
• 1186304-42-6 C₃₉H₄₄O₈ 
• 1366641-92-0 Br^(1-)*C₄₉H₄₄O₅P⁽¹⁺⁾ 
• 905103-73-3 [(4-bromo-3-methoxybenzyl)oxy](tert-butyl)dimethylsilane 
• 1403331-17-8 N-(4-fluorobenzyl)-4-(2-{[4-(hydroxymethyl)-2-methoxyphenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide 
• 1403330-19-7 4-(2-{[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-methoxyphenyl]amino}-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide 
• 1403330-18-6 N-[4-(2-{[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-methoxyphenyl]-amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)-acetamide 
• 1403330-17-5 2-[(4-bromo-3-methoxybenzyl)(ethyl)amino]-2-methylpropan-1-ol 
• 17100-70-8 2-(4-bromo-3-methoxy-benzyloxy)-tetrahydro-pyran 

Relevant academic research and scientific papers

Palladium-Catalzyed Atroposelective 16-Membered Macrocyclization: Total Synthesis of Isoplagiochin D?

Isoplagiochin D is a ring-strained macrocyclic bisbibenzylis, which showed stable axial chirality in one biaryl structure, and semistable axial chirality in the other biaryl moiety. We reported here an unprecedented example for the catalytically asymmetri

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

Vanadium-Catalyzed Oxidative Intramolecular Coupling of Tethered Phenols: Formation of Phenol-Dienone Products

A mild and efficient method for the vanadium-catalyzed intramolecular coupling of tethered free phenols is described. The corresponding phenol-dienone products are prepared directly in good yields with low catalyst loadings. Electronically diverse tethered phenol precursors are well tolerated, and the catalytic method was effectively applied as the key step in syntheses of three natural products and a synthetically useful morphinan alkaloid precursor.

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persis

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

The effect of carboxylate position on the structure of a metal organic framework derived from cyclotriveratrylene

Two cyclotriveratrylene-based ligands H3L1 and H3L2 have been synthesised using microwave heating and used in the formation of 1 [Zn2(L1)(DMA)2(CH3COO)] and 2 [Zn

Substituted hydroxystilbenes and their therapeutic applications

It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.

Discovery of EBI-907: A highly potent and orally active B-RafV600Einhibitor for the treatment of melanoma and associated cancers

A novel series of pyrazolo[3,4-c]isoquinoline derivatives was discovered as B-RafV600Einhibitors through scaffold hopping based on a literature lead PLX4720. Further SAR exploration and optimization led to the discovery of potent B-RafV600

Rim-functionalized cryptophane-111 derivatives via heterocapping, and their xenon complexes

Capping of cyclotriphenolene (3a) by the more available cyclotriguaiacylene (3c) or trisbromocyclotriphenolene (3b) gives the first rim-functionalized cryptophane-111 derivatives. Crystal structures of the xenon complexes reveal high cavity packing coeffi